Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 36

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 36
---
 vesting of incentive awards under our incentive plans are, once issued, eligible for sale in the public market, subject to any lock-up agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144. Furthermore, shares of our Common Stock reserved for future issuance under our incentive plan may become available for sale in future. The market price of shares of our Common Stock could drop significantly if the holders of the shares of Common Stock described above sell them or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future offerings of shares of our Common Stock or other securities. 13 Certain existing securityholders purchased our securities at a price below the current trading price of such securities, and may experience a positive rate of return based on the current trading price. Future investors in us may not experience a similar rate of return. Certain of our securityholders, including the Selling Securityholder, acquired our securities at prices below the current trading prices of our Common Stock and Public Warrants and may experience a positive rate of return ranging from $0.00 to $7.80 based on the current trading prices. In particular, the effective purchase prices at which certain Legacy CERo Stockholders and the Sponsor acquired their shares of our Common Stock are generally substantially less than the Initial Public Offering price of $1,000.00 per share, after giving effect to the Exchange Ratio (as defined in the Business Combination Agreement). Consequently, these securityholders may have an incentive to sell their shares of our Common Stock even if the trading price is below the price paid by investors in the Initial Public Offering, which could cause the market price of our Common Stock to decline. Such stockholders may realize a positive rate of return on the sale of their shares of Common Stock covered by this prospectus even if the market price per share of our Common Stock is below $9.80 per share. On May 22, 2025, the closing prices of our Common Stock and our Public Warrants as reported on the Nasdaq were $0.525 per share and $0.016 per Public Warrant, respectively. While the Selling Securityholder may experience a positive rate of return based on the current trading price, public securityholders may not experience a similar rate of return on the securities they purchased due to differences in the purchase prices they paid and the trading price at the time of sale and may instead experience a negative rate of return on their investment. Holders of our W